NYSE:ELANElanco Animal Health Stock Price, Forecast & News

$23.75

+1.22 (+5.42 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$23.08

Now: $23.75▼

$24.14

50-Day Range

$18.94

MA: $21.78▼

$24.93

52-Week Range

$15.17

Now: $23.75▼

$35.46

Volume5.86 million shs

Average Volume5.28 million shs

Market Capitalization$9.47 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.86

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production. It sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated has a research and development collaboration with AgBiome, Inc. to develop nutritional health products for swine. The company was founded in 1954 and is headquartered in Greenfield, Indiana.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Elanco Animal Health has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.20, Elanco Animal Health has a potential upside of 22.9% from its current price of $23.75.
Amount of Analyst Coverage
Elanco Animal Health has only been the subject of 4 research reports in the past 90 days.

2.2 Community Rank

Outperform Votes
Elanco Animal Health has received 97 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Elanco Animal Health has received 125 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Elanco Animal Health has received 56.31% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Elanco Animal Health and other stocks. Vote “Outperform” if you believe ELAN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ELAN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Elanco Animal Health does not currently pay a dividend.
Dividend Growth
Elanco Animal Health does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Elanco Animal Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $170,810.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.12% of the stock of Elanco Animal Health is held by insiders.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Elanco Animal Health are expected to grow by 52.24% in the coming year, from $0.67 to $1.02 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Elanco Animal Health is -1,187.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Elanco Animal Health is -1,187.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Elanco Animal Health has a PEG Ratio of 2.60. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Elanco Animal Health has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.88 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:ELAN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.elanco.com

Phone877-352-6261

Debt

Debt-to-Equity Ratio0.31

Current Ratio4.41

Quick Ratio2.97

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio35.45

P/E Growth2.6

Sales & Book Value

Annual Sales$3.07 billion

Price / Sales3.08

Cash Flow$2.00 per share

Price / Cash Flow11.86

Book Value$14.87 per share

Price / Book1.60

Profitability

EPS (Most Recent Fiscal Year)$1.06

Net Income$67.90 million

Net Margins-0.42%

Return on Equity6.10%

Return on Assets3.85%

Miscellaneous

Employees6,080

Outstanding Shares398,890,000

Market Cap$9.47 billion

Next Earnings Date8/11/2020 (Estimated)

OptionableOptionable

Receive ELAN News and Ratings via Email

Sign-up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.

Elanco Animal Health (NYSE:ELAN) Frequently Asked Questions

How has Elanco Animal Health's stock been impacted by COVID-19 (Coronavirus)?

Elanco Animal Health's stock was trading at $23.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ELAN stock has increased by 0.1% and is now trading at $23.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Elanco Animal Health?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Elanco Animal Health.

When is Elanco Animal Health's next earnings date?

Elanco Animal Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Elanco Animal Health.

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health (NYSE:ELAN) announced its earnings results on Thursday, May, 7th. The company reported $0.13 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.24 by $0.11. The business had revenue of $657.70 million for the quarter, compared to analysts' expectations of $720.19 million. Elanco Animal Health had a positive return on equity of 6.10% and a negative net margin of 0.42%. The company's revenue was down 10.0% on a year-over-year basis. During the same period last year, the business posted $0.25 EPS. View Elanco Animal Health's earnings history.

What price target have analysts set for ELAN?

10 analysts have issued twelve-month price objectives for Elanco Animal Health's shares. Their forecasts range from $25.00 to $34.00. On average, they anticipate Elanco Animal Health's stock price to reach $29.20 in the next year. This suggests a possible upside of 22.9% from the stock's current price. View analysts' price targets for Elanco Animal Health.

Has Elanco Animal Health been receiving favorable news coverage?

News stories about ELAN stock have trended neutral on Saturday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Elanco Animal Health earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutElanco Animal Health.

Who are some of Elanco Animal Health's key competitors?

Some companies that are related to Elanco Animal Health include ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TKPYY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), Beigene (BGNE), GALAPAGOS NV/S (GLPG) and Catalent (CTLT). View all competitors.

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), Walt Disney (DIS), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Home Depot (HD) and Pfizer (PFE).

Who are Elanco Animal Health's key executives?

Elanco Animal Health's management team includes the following people:

Mr. Jeffrey N. Simmons, Pres, CEO & Director (Age 52)
Mr. Todd S. Young, Exec. VP & CFO (Age 47)
Mr. David S. Kinard, Exec. VP of HR (Age 52)
Ms. Sarena S. Lin, Exec. VP of Elanco USA, Corp. Strategy & Global Marketing (Age 48)
Mr. David Alan Urbanek, Exec. VP of Manufacturing & Quality (Age 53)

When did Elanco Animal Health IPO?

(ELAN) raised $1.4 billion in an initial public offering on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

What is Elanco Animal Health's stock symbol?

Elanco Animal Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELAN."

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (8.63%), Janus Henderson Group PLC (7.72%), Wellington Management Group LLP (7.62%), BlackRock Inc. (5.32%), State Street Corp (3.17%) and Aristotle Capital Management LLC (2.73%). Company insiders that own Elanco Animal Health stock include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral and Todd S Young. View institutional ownership trends for Elanco Animal Health.

Which institutional investors are selling Elanco Animal Health stock?

ELAN stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Invesco Ltd., Deutsche Bank AG, Balyasny Asset Management LLC, Wellington Management Group LLP, Eastern Bank, Connors Investor Services Inc., and Nippon Life Global Investors Americas Inc.. View insider buying and selling activity for Elanco Animal Health.

Which institutional investors are buying Elanco Animal Health stock?

ELAN stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Aristotle Capital Management LLC, Primecap Management Co. CA, State Street Corp, CIBC World Markets Inc., BlackRock Inc., Wafra Inc., and York Capital Management Global Advisors LLC. Company insiders that have bought Elanco Animal Health stock in the last two years include David Alan Urbanek, Dawei Li, Deborah Turner Kochevar, Jeffrey N Simmons, John P Bilbrey, Lawrence Erik Kurzius, Michael J Harrington, Michael-Bryant Hicks, R David Hoover, Ramiro Martin Cabral, and Todd S Young. View insider buying and selling activity for Elanco Animal Health.

How do I buy shares of Elanco Animal Health?

Shares of ELAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Elanco Animal Health's stock price today?

One share of ELAN stock can currently be purchased for approximately $23.75.

How big of a company is Elanco Animal Health?

Elanco Animal Health has a market capitalization of $9.47 billion and generates $3.07 billion in revenue each year. The company earns $67.90 million in net income (profit) each year or $1.06 on an earnings per share basis. Elanco Animal Health employs 6,080 workers across the globe.

What is Elanco Animal Health's official website?

The official website for Elanco Animal Health is www.elanco.com.

How can I contact Elanco Animal Health?

Elanco Animal Health's mailing address is 2500 INNOVATION WAY, GREENFIELD IN, 46140. The company can be reached via phone at 877-352-6261.

This page was last updated on 6/6/2020 by MarketBeat.com Staff